Daily Summary
WHO is launching a global campaign on World Health Day 2025 to improve maternal and newborn care and overall women's health. Eli Lilly expects trial data on its new obesity pill in April 2025, highlighting its potential role in treating obesity without directly targeting Alzheimer’s disease. Meanwhile, Project 2025, backed by the Heritage Foundation and former President Trump, proposes policy changes that could reverse recent U.S. healthcare improvements, risking increased costs and reduced access to essential services.
Eli Lilly Exec Expects Obesity Pill Data in April 2025
Eli Lilly anticipates releasing data from its late-stage trial on orforglipron, an obesity pill that mimics GLP-1, in April 2025. The company's executive is cautious about its direct impact on Alzheimer’s, suggesting it may benefit conditions like obesity and stroke instead.
How Project 2025 Threatens American Health
Project 2025 could reverse critical health care advances—such as insulin cost caps, Medicare drug-price negotiations, and Medicaid protections—potentially jeopardizing the health of millions of Americans.
World Health Day 2025: Healthy Beginnings, Hopeful Futures
WHO launches its World Health Day 2025 campaign to improve maternal and newborn health by ending preventable deaths and supporting women’s long-term well-being.